Completed PHASE4 INTERVENTIONAL 2-arm NCT02630290

Addition of Dexmedetomidine to Ropivacaine-induced Supraclavicular Block (ADRIB Trial) (ADRIB)

Addition of Dexmedetomidine to Ropivacaine-induced Supraclavicular Plexus Block, a Randomized Controlled Study

Sponsor: Guangzhou First People's Hospital

Conditions Forearm Injuries Hand Injuries Radius Fractures Ulna Fractures Wrist Injuries

Interventions Ropivacaine Ropivacaine + Dexmedetomidine

Updated 6 times since 2017 Last updated: Aug 10, 2016 Started: Dec 31, 2015 Primary completion: Jun 30, 2016 Completion: Jun 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Forearm Injuries and Hand Injuries, this trial is completed. The trial is conducted by Guangzhou First People's Hospital and has accumulated 6 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jun 2017 — Jun 2018 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2017 [monthly]

Completed PHASE4

First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Guangzhou First People's Hospital

Data source: Guangzhou First People's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China